PLM60

DRUG2 trials

Sponsors

Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Peripheral T Cell LymphomaSmall Cell Lung Cancer

Phase 1

PLM60 for Peripheral T Cell Lymphoma (PTCL)

WithdrawnNCT03553914

Conjupro Biotherapeutics, Inc.Peripheral T Cell Lymphoma

Start: 2021-01-31End: 2025-01-31Updated: 2020-10-19

Phase 2

A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

TerminatedNCT04352413

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Small Cell Lung Cancer

Start: 2020-06-18End: 2022-04-29Updated: 2024-03-07